120 related articles for article (PubMed ID: 6226856)
1. Chlorozotocin treatment of advanced gastrointestinal cancer.
Veronesi A; Magri MD; Tirelli U; Galligioni E; Figoli F; Zagonel V; Tumolo S; Grigoletto E
Med Pediatr Oncol; 1983; 11(5):365-6. PubMed ID: 6226856
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.
Lawton JO; Giles GR; Hall J; MacAdam A; Hall R; Matheson T; Bird G
Cancer Treat Rep; 1981; 65(1-2):13-15. PubMed ID: 6452945
[TBL] [Abstract][Full Text] [Related]
3. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.
Moertel CG; Lefkopoulo M; Lipsitz S; Hahn RG; Klaassen D
N Engl J Med; 1992 Feb; 326(8):519-23. PubMed ID: 1310159
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of chlorozotocin.
Gralla RJ; Tan CT; Young CW
Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.
Talley RW; Samson MK; Brownlee RW; Samhouri AM; Fraile RJ; Baker LH
Eur J Cancer (1965); 1981 Mar; 17(3):337-43. PubMed ID: 6455296
[No Abstract] [Full Text] [Related]
6. Chlorozotocin: results in colorectal carcinoma treated with high and low doses. A Southwest Oncology Group study.
Haas CD; McCracken JD; Vaughn CB; Stephens RL; Bukowski RM; Eyre HJ
Invest New Drugs; 1984; 2(4):401-4. PubMed ID: 6239836
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of chlorozotocin in advanced large bowel carcinoma. A cooperative study between two institutions.
Schutt AJ; Hoth D; Moertel CG; Schein PS; Rubin J; O'Connell MJ
Am J Clin Oncol; 1984 Oct; 7(5):507-11. PubMed ID: 6239538
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
[TBL] [Abstract][Full Text] [Related]
10. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial with chlorozotocin in advanced colorectal cancer.
Bleiberg H; Rozencweig M; Michel J; Clavel M; Longeval E; Feremans W; Bondue H; Lardinois J; Crespeigne N; Kenis Y
Eur J Cancer Clin Oncol; 1981 Aug; 17(8):863-6. PubMed ID: 6459936
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of chlorozotocin in metastatic sarcomas.
Presant CA; Bartolucci AA
Med Pediatr Oncol; 1984; 12(1):25-7. PubMed ID: 6230516
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ
Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of chlorozotocin in advanced breast cancer.
Edmonson JH; Green SJ; Ingle JN; Ahmann DL; Disel HF; Creagan ET
Cancer Treat Rep; 1981; 65(5-6):537-8. PubMed ID: 6453648
[No Abstract] [Full Text] [Related]
17. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of chlorozotocin in refractory multiple myeloma.
Forman WB; Cohen HJ; Bartolucci AA; Manning G
Cancer Treat Rep; 1984 Nov; 68(11):1409-10. PubMed ID: 6238673
[No Abstract] [Full Text] [Related]
19. Phase II study of chlorozotocin in islet cell carcinoma. A southwest Oncology Group study.
Bukowski RM; McCracken JD; Balcerzak SP; Fabian CJ
Cancer Chemother Pharmacol; 1983; 11(1):48-50. PubMed ID: 6309425
[TBL] [Abstract][Full Text] [Related]
20. Phase I studies on chlorozotocin.
Hoth D; Woolley P; Green D; Macdonald J; Schein P
Clin Pharmacol Ther; 1978 Jun; 23(6):712-22. PubMed ID: 148344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
